Allan Oberman

Allan Oberman is the President & Chief Executive Officer (CEO) of Apotex. He leads a workforce more than 6,500 people, driving our strategic direction and advancing our vision of serving patients and consumers along their health journey.

Allan brings four decades of corporate experience, including 20 years in the pharmaceutical industry. His career journey includes serving as CEO of Concordia International Corp. and Sagent Pharmaceuticals Inc. He also held several key positions at Teva Pharmaceuticals, including President and CEO of Teva Canada (formerly Novopharm Limited), COO of Teva International Group, President of Teva EMIA, and President and CEO of Teva Americas Generics. His expertise spans strategy development, business growth, execution excellence, international market expansion, and global partnership.

Allan has nearly three decades of corporate governance experience. He has served on numerous boards, including as Chairman of the Canadian Generic Pharmaceutical Association and Vice-Chairman of the U.S. Association for Accessible Medicines, and is a member of the International Generic and Biosimilar Medicines Association and Canadian Pharmaceutical Manufacturers and Exporters Alliance.

Allan holds an MBA from the Schulich School of Business, York University, and a BA from Western University.